163 related articles for article (PubMed ID: 11772238)
1. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer.
Mitsiades CS; Koutsilieris M
Expert Opin Investig Drugs; 2001 Jun; 10(6):1099-115. PubMed ID: 11772238
[TBL] [Abstract][Full Text] [Related]
2. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Bogdanos J; Karamanolakis D; Tenta R; Tsintavis A; Milathianakis C; Mitsiades C; Koutsilieris M
Endocr Relat Cancer; 2003 Jun; 10(2):279-89. PubMed ID: 12790789
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
[TBL] [Abstract][Full Text] [Related]
4. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
5. Androgens, antiandrogens and androgen receptor abnormalities.
Kuil CW; Brinkmann AO
Eur Urol; 1996; 29 Suppl 2():78-82. PubMed ID: 8717468
[TBL] [Abstract][Full Text] [Related]
6. Implications of insulin-like growth factor-I for prostate cancer therapies.
Kojima S; Inahara M; Suzuki H; Ichikawa T; Furuya Y
Int J Urol; 2009 Feb; 16(2):161-7. PubMed ID: 19183230
[TBL] [Abstract][Full Text] [Related]
7. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
Koutsilieris M; Mitsiades C; Dimopoulos T; Vacalicos J; Lambou T; Tsintavis A; Milathianakis C; Bogdanos J; Karamanolakis D
Expert Opin Investig Drugs; 2002 Feb; 11(2):283-93. PubMed ID: 11829717
[TBL] [Abstract][Full Text] [Related]
8. Insulin-Like Growth Factor (IGF) family and prostate cancer.
Gennigens C; Menetrier-Caux C; Droz JP
Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
[TBL] [Abstract][Full Text] [Related]
9. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
11. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer.
Iglesias-Gato D; Chuan YC; Wikström P; Augsten S; Jiang N; Niu Y; Seipel A; Danneman D; Vermeij M; Fernandez-Perez L; Jenster G; Egevad L; Norstedt G; Flores-Morales A
Carcinogenesis; 2014 Jan; 35(1):24-33. PubMed ID: 24031028
[TBL] [Abstract][Full Text] [Related]
12. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
13. [Hormone Resistance and Neuroendocrine Differentiation Due to Accumulation of Genetic Lesions during Clonal Evolution of Prostate Cancer].
Mikhaylenko DS; Efremov GD; Sivkov AV; Zaletaev DV
Mol Biol (Mosk); 2016; 50(1):34-43. PubMed ID: 27028809
[TBL] [Abstract][Full Text] [Related]
14. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
15. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
16. Celebrating the 80th anniversary of hormone ablation for prostate cancer.
Zoubeidi A; Ghosh PM
Endocr Relat Cancer; 2021 Jul; 28(8):T1-T10. PubMed ID: 34187942
[TBL] [Abstract][Full Text] [Related]
17. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor: past, present and future.
Schmidt LJ; Tindall DJ
Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
[TBL] [Abstract][Full Text] [Related]
19. Castration-resistant prostate cancer: locking up the molecular escape routes.
Attar RM; Takimoto CH; Gottardis MM
Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
